Workshops and Panels

Speakers:

The financial crisis has changed the international biopharmaceutical landscape dramatically. In China, a unique set of circumstances, including government funding, big pharma interest, and continued VC funding, makes the current climate there more positive than elsewhere in the world. Learn from financial experts focused on China’s life science industry, what opportunities and challenges the future may hold.

Dwindling pipelines and shrinking revenue are problems most pharmaceutical companies are facing today. To make R&D more efficient, many of them are building virtual development groups, especially in China where costs are much lower. As a result, the CRO/CMO industry is booming, and in fact, two of the largest CRO facilities in the world are currently being built in China. This panel will examine the impact of the outsourcing revolution in China and how it is creating opportunities for increased productivity and collaborative development projects as well as lowered costs.

The China government has created a strong financial stimulus to build a solid domestic biotech/biopharma industry. This has resulted in the launch of several major life science clusters throughout China. Officials and executives from the top life science parks and agencies in China present the advantages each region offers and specific incentive programs, as well as a “where to” and “how to” approach to establishing a presence in China.

Commercializing early stage technology is a challenge anywhere in the world. Starting with essentially a clean sheet, China has the opportunity to do things differently. This also means that there is little experience and expertise at hand to draw from. The panel examines what is currently working in China, what is not, what lessons can be gleaned from the experience in the U.S. and Europe, and how to be successful at moving technology developed in China from the lab into the clinic.

Speaker:

The world's capital markets crisis has intensified the importance of licensing and collaborations as a means for companies to finance their growth and progress.  Foreign pharmaceutical and biotech companies seeking profitable licensing and collaboration opportunities are looking to China as a vital market for R&D, manufacturing, and commercialization.  How can Chinese companies prepare themselves for licensing and collaboration transactions with foreign entities? What preparations should be made by foreign companies to avoid pitfalls in these agreements? This presentation will examine and address:

• The Basic Building Blocks of Agreements, From Simple to Complex
• Advance Preparation Necessary to Properly Prepare for Negotiating an Agreement
• The Terms of IP Licenses in Detail and Review Negotiating Strategies
• Ten Rules to Complete Your Deals Successfully

A partnering agreement with a pharmaceutical company may be one of the most complex transactions a biotech company will enter into as part of its business operations. Understanding the negotiation process, the structure of the agreement and the significance and potential pitfalls of certain critical terms can play a big role in forming a successful collaboration. This panel will discuss the steps involved in entering into a partnering deal, from preparation to negotiation to execution and implementation.

China's drug market is growing at an enormous speed and has become an essential market for all big pharma and biotech players. In addition to increasing direct investment into China, overseas players have different initiatives and plans in forming strategic alliances with local companies in terms of R&D, manufacturing, commercialization as well as service. Influenced by the Chinese government incentives and the tremendously growing talent pool, Chinese life sciences companies are getting competitive on an international level. As a consequence, more cross-border M&As will also take place in this industry. Our seasoned speakers in this panel will address in detail what are the opportunities and challenges accompanying such exciting transactions.

This panel will discuss challenges faced by pharmaceutical companies in conducting R&D activities in China especially issues and concerns relating to patent protection, and strategies for protecting and strengthening IPRs in China and worldwide.